速效胰岛素类似物与人胰岛素在胰岛素泵中的应用研究

目的:探索速效胰岛素类似物-门冬胰岛素(诺和锐)与人胰岛素(优泌林R)治疗2型糖尿病的疗效特点、安全性.方法:选取2型糖尿病患者60例,随机分成A组和B组,每组30例患者,A组用诺和锐、B组用优泌林R作为泵用胰岛素进行CSⅡ强化治疗.结果:经过治疗,两组空腹血糖、餐后2h血糖均有显著降低,与治疗前比较差异有统计学意义(P＜0.05)；A和B组血糖达标时间分别为(4.20土1.86)d和(6.28±1.89)d,门冬胰岛素组达标时间较短(P＜0.05)；控制血糖达标时,胰岛素用量显著低于优泌林R组(P＜0.05)；诺和锐的用量较优泌林R的用量少,低血糖发生率较优泌林R组低.结论:门冬胰岛素是一种有效的抗糖尿病药物.

Application research of rapidly acting insulin aspart and human insulin in insulin pump therapy

Objective: To compare the effectiveness,security and application characteristics of rapidly acting insulin analogues(aspart) and human insulin(Humulin R) used in insulin pump in treating type 2 diabetes.Methods: Collected 60 type 2 diabetic patients and randomly divided into 2 groups with 30 patients in each group.Group A was treated with insulin aspart and group B with Humulin R.Results: After treatment,the fasting blood glucose and 2 hour post-meal blood sugar significantly decreased in the two groups(P<0.05).Compared with the group B,the treatment of insulin aspart shortened the therapeutic time(4.20±1.86d vs 6.28±1.89d),reduced the amount of insulin dose in blood glucose control and the daily insulin dosage(P<0.05).The hypoglycemia incidence in group A was significantly lower than that in group B.Conclusion: Insulin aspart is a kind of effective anti-diabetic drug in CSII therapy.